title: Landiolol, a new ultra-short-acting beta1-blocker, reduces anaesthetic requirement during sevoflurane/N(2)O/fentanyl anaesthesia in surgical patients.
abstract: OBJECTIVE
  It is known that esmolol, a short-acting beta1-blocker, reduces anaesthetic requirement. In this study, we evaluated whether a low dose of landiolol, a new ultra-short-acting beta1-blocker, can reduce the sevoflurane requirement.
  
  
  METHODS
  Twenty-five patients undergoing hip surgery were randomly divided into two groups. Group A (n = 13) received landiolol (bolus injection of 0.031 mg.kg(-1) and continuous infusion at a rate of 0.01 mg.kg(-1).min(-1)). Group B (n = 12) received physiological saline. Landiolol and physiological saline were started before the induction of anaesthesia and continued until the end of anaesthesia. Anaesthesia was maintained with sevoflurane, 60% N(2)O and fentanyl. Sevoflurane concentration was controlled to keep the bispectral index at approximately 50. The end-tidal sevoflurane concentration and haemodynamics were measured during anaesthesia.
  
  
  RESULTS
  The average end-tidal sevoflurane concentration in group A was significantly lower than that in group B (1.2 +/- 0.30 vs. 1.8 +/- 0.3%, P < 0.01). Maximum values of systolic arterial pressure showed no difference between the groups, whereas the maximum value of heart rate in group A was significantly less than that in group B (61 +/- 10 vs. 76 +/- 14 beats min(-1), P < 0.05).
  
  
  CONCLUSIONS
  The results suggest that a low dose of landiolol significantly reduces the intraoperative sevoflurane requirement during sevoflurane/N(2)O/fentanyl anaesthesia in patients undergoing hip surgery.
authors.affiliation: Department of Anaesthesia, Nagasaki Rosai Hospital, Sasebo, Japan. tanestht@yahoo.co.jp
authors.forename: Takahiro
authors.initials: T
authors.lastname: Tanabe
authors.forename: Makoto
authors.initials: M
authors.lastname: Fukusaki
authors.forename: Arihiro
authors.initials: A
authors.lastname: Fujinaga
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ando
authors.forename: Kazunori
authors.initials: K
authors.lastname: Yamashita
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Terao
authors.forename: Koji
authors.initials: K
authors.lastname: Sumikawa
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000368:Aged; D000369:Aged, 80 and over; D000758:Anesthesia / Q000379:methods*; D000777:Anesthetics / Q000494:pharmacology*; D005260:Female; D005283:Fentanyl / Q000494:pharmacology; D006615:Hip / Q000601:surgery*; D006801:Humans; D008297:Male; D008738:Methyl Ethers / Q000494:pharmacology; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology*; D009609:Nitrous Oxide / Q000494:pharmacology; D000077149:Sevoflurane; D013997:Time Factors; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000319:Adrenergic beta-Antagonists; D000777:Anesthetics; D008738:Methyl Ethers; D009025:Morpholines; D000077149:Sevoflurane; C077049:landiolol; D014508:Urea; D009609:Nitrous Oxide; D005283:Fentanyl